Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

The effects of rosuvastatin on malondialdehyde level and superoxide dismutase activity in plasma and liver of normolipidemic rats (CROSBI ID 640549)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Vukšić, Antonija ; Božina, Tamara ; Rašić, Dubravka ; Žunec, Suzana ; Konjevoda, Paško ; Lovrić, Jasna ; Bradamante, Vlasta The effects of rosuvastatin on malondialdehyde level and superoxide dismutase activity in plasma and liver of normolipidemic rats // Book of abstracts of the 8th Croatian Congress of Pharmacology with International Participation / Boban, Mladen (ur.). Split: Hrvatsko farmaceutsko društvo, 2016. str. 70-71

Podaci o odgovornosti

Vukšić, Antonija ; Božina, Tamara ; Rašić, Dubravka ; Žunec, Suzana ; Konjevoda, Paško ; Lovrić, Jasna ; Bradamante, Vlasta

engleski

The effects of rosuvastatin on malondialdehyde level and superoxide dismutase activity in plasma and liver of normolipidemic rats

Introduction: Statins have been shown to possess antioxidant effects and our previous results showed that simvastatin significantly decrease malondialdehyde (MDA) levels in plasma and tissue of rats. Here we wanted to investigate the influence of rosuvastatin (ROSU) on MDA level and superoxide dismutase (SOD) activity in plasma and liver of rats, both considered to be markers of oxidative stress. Material and Methods: Thirty-six male Wistar rats were divided in one control group (saline) and two experimental groups (ROSU 5 mg/kg/day and 10 mg/kg/day). Drug and saline were given orally for period of 3 weeks. Animals were sacrificed with ether 24 hours after last dose. Blood samples were obtained directly from heart and liver tissue was rinsed with saline. MDA in plasma was measured with high performance liquid chromatography using commercially HPLC kits, while in liver using Drury method. SOD activity was measured in plasma with sensitive spectrophotometric assay and in liver using Flohé and Ötting method. Data were analyzed using ANOVA test. Results are expressed as the means and SDs. Results: ROSU in both doses decreased MDA level in liver but decrease was significant (p<0.05) only after administration of low dose (ROSU 5 mg vs. control: 0.863±0.182 vs. 1.14±0.316). In plasma higher dose of ROSU showed tendency to decrease, while lower dose tendency to increase MDA level. SOD activity with both doses was increased in plasma and decreased in liver, but none were statistically significant. Conclusion: According to these results we suggest that rosuvastatin exerts weaker antioxidative effect than simvastatin.

rosuvastatin ; malondialdehyde ; superoxide dismutase ; rats

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

70-71.

2016.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Book of abstracts of the 8th Croatian Congress of Pharmacology with International Participation

Boban, Mladen

Split: Hrvatsko farmaceutsko društvo

Podaci o skupu

8th Croatian Congress of Pharmacology with international participation

poster

15.09.2016-18.09.2016

Split, Hrvatska

Povezanost rada

Temeljne medicinske znanosti